Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations (Unaudited)

v3.7.0.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Revenue:        
Tc 99m tilmanocept sales revenue $ 4,399 $ 13,199
Tc 99m tilmanocept license revenue 100,000 245,950 100,000 500,000
Grant and other revenue 511,599 916,811 1,091,629 1,602,446
Total revenue 611,599 1,167,160 1,191,629 2,115,645
Cost of goods sold 807 2,296
Gross profit 611,599 1,166,353 1,191,629 2,113,349
Operating expenses:        
Research and development 1,185,874 2,019,211 1,891,148 4,091,482
Selling, general and administrative 4,249,584 1,387,817 7,272,018 4,020,943
Total operating expenses 5,435,458 3,407,028 9,163,166 8,112,425
Loss from operations [1] (4,823,859) (2,240,675) (7,971,537) (5,999,076)
Other income (expense):        
Interest income (expense), net 44,649 (2,992) 68,761 (2,235)
Equity in loss of R-NAV, LLC (2,920) (15,159)
Loss on disposal of investment in R-NAV, LLC (39,732) (39,732)
Change in fair value of financial instruments 12,872 1,469,928 153,357 2,595,287
Loss on extinguishment of debt (1,314,102)
Other, net (16,673) (126) (38,277) (37,418)
Total other income (expense), net 40,848 1,424,158 (1,130,261) 2,500,743
Loss before income taxes (4,783,011) (816,517) (9,101,798) (3,498,333)
Benefit from income taxes 1,631,234 0 3,085,406
Loss from continuing operations (3,151,777) (816,517) (6,016,392) (3,498,333)
Discontinued operations, net of tax effect:        
Loss from discontinued operations (82,376) (5,864,790) (338,237) (6,869,223)
Gain (loss) on sale (1,953,378) 86,748,123
Net income (loss) (5,187,531) (6,681,307) 80,393,494 (10,367,556)
Less income (loss) attributable to noncontrolling interest 33 (116) (169) (357)
Net income (loss) attributable to common stockholders $ (5,187,564) $ (6,681,191) $ 80,393,663 $ (10,367,199)
Income (loss) per common share (basic):        
Continuing operations (in dollars per share) $ (0.02) $ (0.01) $ (0.04) $ (0.03)
Discontinued operations (in dollars per share) (0.01) (0.03) 0.54 (0.04)
Attributable to common stockholders (in dollars per share) $ (0.03) $ (0.04) $ 0.50 $ (0.07)
Weighted average shares outstanding (basic) (in shares) 161,910,792 155,382,368 161,147,873 155,345,231
Income (loss) per common share (diluted):        
Continuing operations (in dollars per share) $ (0.02) $ (0.01) $ (0.04) $ (0.03)
Discontinued operations (in dollars per share) (0.01) (0.03) 0.52 (0.04)
Attributable to common stockholders (in dollars per share) $ (0.03) $ (0.04) $ 0.49 $ (0.07)
Weighted average shares outstanding (diluted) (in shares) 161,910,792 155,382,368 165,631,000 155,345,231
[1] Income (loss) from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.